UK markets close in 6 hours 15 minutes

TherapeuticsMD, Inc. (TXMD)

NasdaqGS - NasdaqGS Delayed price. Currency in USD
Add to watchlist
1.8800+0.0200 (+1.08%)
At close: 04:00PM EDT
1.9400 +0.06 (+3.19%)
After hours: 07:24PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 21.68M
Enterprise value 25.36M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)15.08
Price/book (mrq)0.74
Enterprise value/revenue 19.48
Enterprise value/EBITDA -3.34

Trading information

Stock price history

Beta (5Y monthly) 1.04
52-week change 3-47.92%
S&P500 52-week change 323.06%
52-week high 34.7200
52-week low 31.8600
50-day moving average 32.2486
200-day moving average 32.7622

Share statistics

Avg vol (3-month) 322.18k
Avg vol (10-day) 331.59k
Shares outstanding 511.53M
Implied shares outstanding 611.53M
Float 89.91M
% held by insiders 13.78%
% held by institutions 128.20%
Shares short (28 Mar 2024) 445.2k
Short ratio (28 Mar 2024) 41.74
Short % of float (28 Mar 2024) 40.47%
Short % of shares outstanding (28 Mar 2024) 40.39%
Shares short (prior month 29 Feb 2024) 440.87k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:50
Last split date 309 May 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023


Profit margin 0.00%
Operating margin (ttm)-320.92%

Management effectiveness

Return on assets (ttm)-7.96%
Return on equity (ttm)-23.90%

Income statement

Revenue (ttm)1.3M
Revenue per share (ttm)0.12
Quarterly revenue growth (yoy)-99.30%
Gross profit (ttm)N/A
Net income avi to common (ttm)-7.7M
Diluted EPS (ttm)-0.7400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)4.33M
Total cash per share (mrq)0.38
Total debt (mrq)8.01M
Total debt/equity (mrq)27.33%
Current ratio (mrq)1.72
Book value per share (mrq)2.54

Cash flow statement

Operating cash flow (ttm)-48.14M
Levered free cash flow (ttm)-34.19M